If You'd Invested $1,000 in Moderna Stock 5 Years Ago, Here's How Much You'd Have Today

The COVID-19 pandemic thrust this company's science -- and its stock -- into the spotlight.Five years ago, pharmaceutical company Moderna (MRNA 0.68%) was mostly unknown. It was developing vaccines that induce human immune cells to more effectively fight disease. But the science of DNA-based drugs was on the experimental fringe of the biopharma landscape. Not too many investors were looking to make such a bet.Then the COVID-19 pandemic materialized. As it turns out, the coronavirus was the ideal target for ...